Glp-1 & Gip Drugs:Ozempic, Wegovy-Obesity & Diabetes Therapy

Master the science and clinical applications of GLP-1–based therapies like Ozempic, Wegovy, and Mounjaro

What you'll learn

Explain incretin biology and receptor signaling in diabetes and obesity

Differentiate the mechanisms of GLP-1, GIP, and dual agonist therapies

Analyze multi-organ metabolic effects beyond pancreatic regulation

Evaluate clinical data and therapeutic applications of GLP-1–based drugs

Requirements

No prior knowledge required

Description

GLP-1 receptor agonists and dual GIP/GLP-1 agonists have transformed the treatment of type 2 diabetes, obesity, and cardiometabolic disorders. Drugs like Ozempic, Wegovy, and Mounjaro are no longer just glucose-lowering agents; they are reshaping obesity management, cardiovascular risk reduction, and even liver disease therapy.This course is about GLP-1 & GIP Drugs like Ozempic, Wegovy, and Mounjaro used in Obesity & Diabetes Therapy, and is designed to give you a complete, mechanism-driven understanding of how incretin hormones work, why their biology is so powerful, and how modern therapeutics harness these pathways to benefit the people in need. You will explore the molecular mechanisms of incretin receptors, pancreatic regulation, and multi-organ effects, and then connect this knowledge to real-world therapeutic applications.Whether you are in biotech research, pharmacy, medicine, or academia, this course bridges cutting-edge molecular biology with practical pharmacology and clinical insight.By the end, you’ll be able to:Explain the physiology of GLP-1 and GIP and their complementary roles in glucose regulationUnderstand how receptor signaling differences translate into therapeutic outcomesEvaluate how incretin therapies impact multiple organs: brain, gut, adipose tissue, and liverAnalyze clinical trial data on HbA1c reduction, weight loss, and cardiovascular protectionAppreciate the evolution from GLP-1 analogues to dual agonists, and where the field is going

Overview

Section 1: Chapter 0 – Introduction: Why GLP-1 Therapies Are Transforming Medicine

Lecture 1 Chapter 0 – Introduction: Why GLP-1 Therapies Are Transforming Medicine

Section 2: Chapter 1 – Incretin Biology and Receptor Signaling in Metabolic Health

Lecture 2 Chapter 1 – Incretin Biology and Receptor Signaling in Metabolic Health

Section 3: Chapter 2 – Comparing GLP-1, GIP, and Dual Agonist Mechanisms

Lecture 3 Chapter 2 – Comparing GLP-1, GIP, and Dual Agonist Mechanisms

Section 4: Chapter 3 – Beyond the Pancreas: Multi-Organ Metabolic Effects

Lecture 4 Chapter 3 – Beyond the Pancreas: Multi-Organ Metabolic Effects

Section 5: Chapter 4 – Clinical Evidence and Therapeutic Applications of GLP-1 Drugs

Lecture 5 Chapter 4 – Clinical Evidence and Therapeutic Applications of GLP-1 Drugs

Biotech and pharmaceutical researchers developing metabolic therapies.,Pharmacy, medical, and life science students seeking therapeutic insights.,Clinicians and pharmacists interested in GLP-1–based treatment strategies.,Healthcare and biotech professionals curious about obesity and diabetes drug innovation.